Capturing newly diagnosed ATTR-CM volume, not switching stable tafamidis patients, is the path past ICER's steepest value gap in rare disease.

Tafamidis (Vyndaqel) holds roughly 60% of the ATTR-CM stabilizer market, but the more important fact for a pre-launch entrant is that this market is expanding rapidly, not fixed. An estimated 500,000-plus US patients aged 70 and over with HFpEF have undiagnosed ATTRwt-CM, against only 70,000-100,000 currently diagnosed and treated, and annual new diagnoses are running at 10,000-15,000 as Tc-PYP scintigraphy awareness grows. Acoramidis (Attruby, approved November 2024) has built 15-20% share almost entirely from newly diagnosed patients rather than tafamidis switches, confirming that capturing new diagnosis volume, not displacing the incumbent, is the correct commercial model for a new entrant.

Two structural sub-populations remain underdiagnosed and largely untapped: ATTRv hereditary carriers, including an estimated 100,000-plus African American Val122Ile carriers, most undiagnosed, at a 3-4% carrier rate; and ATTR-PN polyneuropathy, where a 4-5 year misdiagnosis delay, commonly mistaken for CIDP or diabetic neuropathy, hides 5,000-10,000 hereditary patients against only 3,000-4,000 currently diagnosed and treated. The competitive landscape is also mechanistically bifurcating, stabilizers such as tafamidis and acoramidis versus knockdown therapy such as vutrisiran, raising an unresolved commercial question: is a new drug positioned as a stand-alone stabilizer, a combination partner, or a replacement mechanism?

ICER's tafamidis fair-value range sits 12 to 17 times below its list price.

Five questions this report answers:

Q1 - Should a new ATTR-CM stabilizer target newly diagnosed patients or switch stable tafamidis patients?

Q2 - How large is the underdiagnosed ATTRv Val122Ile and ATTR-PN opportunity in the US?

Q3 - What ICER-style value scrutiny should a new ATTR-CM stabilizer plan for at launch?

Q4 - What deliverable formats come with a commissioned US ATTR launch readiness assessment?

Q5 - How large is the expanding addressable ATTR population a new US entrant can target?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#ATTRAmyloidosis #Cardiology #USMarketAccess #RareDisease #LaunchReadiness

Live report page:  https://axlrx.ai/attr-amyloidosis/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/